Comparative effectiveness of liraglutide in the treatment of type 2 diabetes

References

• Wild S Roglic G Green A Sicree R King H Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004 27 5 1047 1053 15111519
   PubMed Web of Science ®Google Scholar
• Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 7258 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A Navarro-Artieda R Ibanez-Nolla J Clinical and economic characteristics associated with type 2 diabetes Rev Clin Esp 12 17 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 2012 55 6 1577 1596 22526604
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Gerstein HC Miller ME Byington RP Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 24 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• Patel A MacMahon S Chalmers J ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 24 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 2 129 139 19092145
   PubMed Web of Science ®Google Scholar
• Turnbull FM Abraira C Anderson RJ Control Group Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 2009 52 11 2288 2298 19655124
   PubMed Web of Science ®Google Scholar
• Ferrannini E Gastaldelli A Miyazaki Y Matsuda M Mari A DeFronzo RA Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis J Clin Endocrinol Metab 2005 90 1 493 500 15483086
   PubMed Web of Science ®Google Scholar
• [No authors listed] UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group Diabetes 1995 44 11 1249 1258 7589820
   PubMed Web of Science ®Google Scholar
• Nauck MA Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications Am J Med 2011 124 Suppl 1 S3 S18 21194578
   PubMed Web of Science ®Google Scholar
• Ford ES Giles WH Mokdad AH Increasing prevalence of the metabolic syndrome among US adults Diabetes Care 2004 27 10 2444 2449 15451914
   PubMed Web of Science ®Google Scholar
• Mottillo S Filion KB Genest J The metabolic syndrome and cardiovascular risk – a systematic review and meta-analysis J Am Coll Cardiol 2010 56 14 1113 1132 20863953
   PubMed Web of Science ®Google Scholar
• Kahn SE Haffner SM Heise MA Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 2006 355 23 2427 2443 17145742
   PubMed Web of Science ®Google Scholar
• Cernea S Raz I Therapy in the early stage: incretins Diabetes Care 2011 34 Suppl 2 S264 S271 21525466
   PubMed Web of Science ®Google Scholar
• Baggio LL Drucker DJ Biology of incretins: GLP-1 and GIP Gastroenterology 2007 132 6 2131 2157 17498508
   PubMed Web of Science ®Google Scholar
• Nauck M Stockmann F Ebert R Creutzfeldt W Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 1986 29 1 46 52 3514343
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 9548 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Knudsen LB Nielsen PF Huusfeldt PO Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J Med Chem 2000 43 9 1664 1669 10794683
   PubMed Web of Science ®Google Scholar
• Montanya E Sesti G A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus Clin Ther 2009 31 11 2472 2488 20109994
   PubMed Web of Science ®Google Scholar
• Sturis J Gotfredsen CF Romer J GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics Br J Pharmacol 2003 140 1 123 132 12967942
   PubMed Web of Science ®Google Scholar
• Rolin B Larsen MO Gotfredsen CF The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice Am J Physiol Endocrinol Metab 2002 283 4 E745 E752 12217892
   PubMed Web of Science ®Google Scholar
• Rutti S Sauter NS Bouzakri K Prazak R Halban PA Donath MY In vitro proliferation of adult human beta-cells PLoS One 2012 7 4 e35801 22563404
   PubMed Web of Science ®Google Scholar
• McClean PL Holscher C Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease Neuropharmacology 2014 76 Pt A 57 67 23973293
   PubMed Web of Science ®Google Scholar
• Raun K von Voss P Gotfredsen CF Golozoubova V Rolin B Knudsen LB Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not Diabetes 2007 56 1 8 15 17192459
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA Mankad S Sokos GG Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 2004 109 8 962 965 14981009
   PubMed Web of Science ®Google Scholar
• Hattori Y Jojima T Tomizawa A A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells Diabetologia 2010 53 10 2256 2263 20593161
   PubMed Web of Science ®Google Scholar
• Elbrond B Jakobsen G Larsen S Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects Diabetes Care 2002 25 8 1398 1404 12145241
   PubMed Web of Science ®Google Scholar
• Watson E Jonker DM Jacobsen LV Ingwersen SH Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide J Clin Pharmacol 2010 50 8 886 894 20133507
   PubMed Web of Science ®Google Scholar
• Jacobsen LV Hindsberger C Robson R Zdravkovic M Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide Br J Clin Pharmacol 2009 68 6 898 905 20002084
   PubMed Web of Science ®Google Scholar
• Flint A Nazzal K Jagielski P Hindsberger C Zdravkovic M Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide Br J Clin Pharmacol 2010 70 6 807 814 21175436
   PubMed Web of Science ®Google Scholar
• Kapitza C Zdravkovic M Hindsberger C Flint A The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen Adv Ther 2011 28 8 650 660 21792552
   PubMed Web of Science ®Google Scholar
• Marre M Shaw J Brandle M LEAD-1 SU study group Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU) Diabet Med 2009 26 3 268 278 19317822
   PubMed Web of Science ®Google Scholar
• Nauck M Frid A Hermansen K LEAD-2 Study Group Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study Diabetes Care 2009 32 1 84 90 18931095
   PubMed Web of Science ®Google Scholar
• Garber A Henry R Ratner R LEAD-3 (Mono) Study Group Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial Lancet 2009 373 9662 473 481 18819705
   PubMed Web of Science ®Google Scholar
• Zinman B Gerich J Buse JB LEAD-4 Study Investigators Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) Diabetes Care 2009 32 7 1224 1230 19289857
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Vaag A Schmitz O Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial Diabetologia 2009 52 10 2046 2055 19688338
   PubMed Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009 374 9683 39 47 19515413
   PubMed Web of Science ®Google Scholar
• Buse JB Sesti G Schmidt WE Liraglutide Effect Action in Diabetes-6 Study Group Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents Diabetes Care 2010 33 6 1300 1303 20332351
   PubMed Web of Science ®Google Scholar
• Pratley RE Nauck M Bailey T 1860-LIRA-DPP-4 Study Group Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 2010 375 9724 1447 1456 20417856
   PubMed Web of Science ®Google Scholar
• Degn KB Juhl CB Sturis J One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 2004 53 5 1187 1194 15111485
   PubMed Web of Science ®Google Scholar
• Mattheus D Marre M Le Thi TD Liraglutide once daily human GLP-1 analog, significantly improves beta-cell function in subjects with type 2 diabetes Diabetes 2008 57 A150
   Web of Science ®Google Scholar
• Matthews DR Vilsbøll T Courrèges J-P Zychma M Falahati A Bode BW Liraglutide improves two indicators of beta cell function – HOMA-B and proinsulin:insulin ratio – in a meta-analysis of 6 clinical trials Diabetologia 2010 53 Suppl 1 S339
   Google Scholar
• Fonseca V Falahati A Zychma M Madsbad S Plutzky J A meta- analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure Diabetologia 2009 52 Suppl 1 S299
   PubMed Web of Science ®Google Scholar
• Fonseca VA Henry RR Tabanera y Palacios R Brett J Plutzky J In subjects with type 2 diabetes, liraglutide, a once-daily human GLP-1 analogue, reduces systolic blood pressure with negligible impact from weight loss Diabetologia 2010 53 Suppl 1 S510
   Google Scholar
• Fonseca V Plutzky J Montanya E Liraglutide, a once-daily human GLP-1 analog, lowers systolic blood pressure (SBP) independently of concomitant antihypertensive treatment Diabetes 2010 59 Suppl 1 A79 (296-OR)
   Google Scholar
• Plutzky J Garber AJ Falahati A Toft AD Poulter NR The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials Eur Heart J 2009 30 Suppl 1 917
   Google Scholar
• Pratley R Nauck M Bailey T One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial Int J Clin Pract 2011 65 4 397 407 21355967
   PubMed Web of Science ®Google Scholar
• Aschebrook-Kilfoy B Ward MH Sabra MM Devesa SS Thyroid cancer incidence patterns in the united states by histologic type, 1992–2006 Thyroid 2011 21 2 125 134 21186939
   PubMed Web of Science ®Google Scholar
• Bjerre Knudsen L Madsen LW Andersen S Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 2010 151 4 1473 1486 20203154
   PubMed Web of Science ®Google Scholar
• Parks M Rosebraugh C Weighing risks and benefits of liraglutide – the FDA’s review of a new antidiabetic therapy N Engl J Med 2010 362 9 774 777 20164475
   PubMed Web of Science ®Google Scholar
• Hegedus L Moses AC Zdravkovic M Le Thi T Daniels GH GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide J Clin Endocrinol Metab 2011 96 3 853 860 21209033
   PubMed Web of Science ®Google Scholar
• Costante G Durante C Francis Z Schlumberger M Filetti S Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls Nat Clin Pract Endocrinol Metab 2009 5 1 35 44 19079272
   PubMedGoogle Scholar
• Noel RA Braun DK Patterson RE Bloomgren GL Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study Diabetes Care 2009 32 5 834 838 19208917
   PubMed Web of Science ®Google Scholar
• Nyborg NC Molck AM Madsen LW Knudsen LB The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species Diabetes 2012 61 5 1243 1249 22338093
   PubMed Web of Science ®Google Scholar
• Vrang N Jelsing J Simonsen L The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis Am J Physiol Endocrinol Metab 2012 303 2 E253 E264 22589391
   PubMed Web of Science ®Google Scholar
• Jensen TM Saha K Steinberg W Assessment of acute pancreatitis in liraglutide type 2 diabetes trials Pancreas 2012 41 1370 1371
   Web of Science ®Google Scholar
• European Medicines Agency Victoza liraglutide EPAR summary for the public Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001026/human_med_001137.jsp&mid=WC0b01ac058001d124 Accessed February 24, 2014
   Google Scholar
• Butler AE Campbell-Thompson M Gurlo T Dawson DW Atkinson M Butler PC Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors Diabetes 2013 62 7 2595 2604 23524641
   PubMed Web of Science ®Google Scholar
• Funch D Gydesen H Tornoe K Major-Pedersen A Chan KA A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared with other antidiabetic drugs Diabetes Obes Metab 2014 16 3 273 275 24199745
   PubMed Web of Science ®Google Scholar
• Buse JB Garber A Rosenstock J Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the liraglutide effect and action in diabetes (LEAD) trials J Clin Endocrinol Metab 2011 96 6 1695 1702 21450987
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 5 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Davidson JA Brett J Falahati A Scott D Mild renal impairment and the efficacy and safety of liraglutide Endocr Pract 2011 17 3 345 355 21700561
   PubMed Web of Science ®Google Scholar
• Speight J Assessing patient satisfaction: concepts, applications, and measurement Value Health 2005 8 Suppl 1 S6 S8 16336490
   PubMed Web of Science ®Google Scholar
• Kolotkin RL Crosby RD Kosloski KD Williams GR Development of a brief measure to assess quality of life in obesity Obes Res 2001 9 2 102 111 11316344
   PubMedGoogle Scholar
• Hermansen K Kolotkin RL Hammer M Zdravkovic M Matthews D Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin Prim Care Diabetes 2010 4 2 113 117 20444662
   PubMed Web of Science ®Google Scholar
• Bode BW Testa MA Magwire M LEAD-3 Study Group Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes Diabetes Obes Metab 2010 12 7 604 612 20590735
   PubMed Web of Science ®Google Scholar
• Davies M Pratley R Hammer M Thomsen AB Cuddihy R Liraglutide improves treatment satisfaction in people with type 2 diabetes compared with sitagliptin, each as an add on to metformin Diabet Med 2011 28 3 333 337 21309842
   PubMed Web of Science ®Google Scholar
• Montanya E Pratley R Nauck M Switching from sitagliptin to liraglutide, in combination with metformin, improves treatment satisfaction in patients with type 2 diabetes Diabetes 2011 60 Suppl 1 A307
   Google Scholar
• Schmidt WE Christiansen JS Hammer M Zychma MJ Buse JB Patient-reported outcomes are superior in patients with type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study Diabet Med 2011 28 6 715 723 21388442
   PubMed Web of Science ®Google Scholar
• Fadini GP Simioni N Frison V Independent glucose and weight-reducing effects of liraglutide in a real-world population of type 2 diabetic outpatients Acta Diabetol 2013 50 6 943 949 23754673
   PubMed Web of Science ®Google Scholar
• Zinman B Schmidt WE Moses A Lund N Gough S Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme Diabetes Obes Metab 2012 14 1 77 82 21883806
   PubMed Web of Science ®Google Scholar
• Ryder REJ Sen-Gupta P Thong KY ABCD Nationwide Liraglutide Audit Contributors Liraglutide is effective across a range of obese body mass indices; findings from the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit Poster 801 presented at the 2012 meeting of the European Association for the Study of Diabetes October 1–5, 2012 Berlin, Germany
   Google Scholar